Compare Cytokinetics Inc (CYTK) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Energy Select Sector SPDR Fund — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Energy Select Sector SPDR Fund trades at $65.09 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is far larger — about 4.7× Cytokinetics Inc's market cap, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| CYTK | XLE | |
|---|---|---|
Market Cap | $8.62B | $40.84B |
Volume | 2,594,626 | 50,409,268 |
Sector | Health | — |
52-Week High | $87.26 | $65.93 |
52-Week Low | $54.76 | $42.61 |
Typical Hold Time | 19 Days | 67 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
XLE trades at $65.24, up 2.93% with strong bullish momentum from moving averages but overbought RSI signals. The energy ETF benefits from oil price surges above $100 and Middle East tensions, though futures traders bet on a 12% sector decline. Dividend yield remains modest with a $0.38 distribution scheduled for September 2026.
Outlook hinges on oil price sustainability amid geopolitical risks and Fed policy. Key risks include oil volatility and strategic reserve releases. Analysts show mixed signals with technical strength but fundamental data gaps warrant caution for energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
